Smarteeva

From the public record

Name	Smarteeva
Tagline	Salesforce-native, AI-powered post-market surveillance platform for medical device manufacturers. [Smarteeva]
Headquarters	Santa Barbara, CA, USA [Crunchbase]
Founded	2018 [The Org]
Stage	Seed [StartupSeeker]
Business Model	SaaS [Smarteeva]
Industry	Healthtech [Smarteeva]
Technology	AI / Machine Learning [Smarteeva]
Geography	North America
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding Label	Seed
Total Disclosed	$500,000+ (estimated) [StartupSeeker]

Links

From the public record

• Website: https://www.smarteeva.com/
• LinkedIn: https://www.linkedin.com/company/smarteeva

The Short Version

From the public record Smarteeva offers a Salesforce-native platform that automates the complex, compliance-heavy post-market surveillance process for medical device manufacturers, a bet that regulatory pressure and manual inefficiency create a durable wedge in a specialized software market. Founded in 2018 by Plarent Ymeri, the company has built an integrated suite on the Salesforce ecosystem to handle complaint management, adverse event reporting, and recall workflows, aiming to replace a patchwork of manual processes and point solutions. The core product differentiates by embedding AI for tasks like risk assessment and duplicate detection, while directly automating the generation and submission of critical reports like FDA Medical Device Reports (MDRs) [Smarteeva].

Key performance claims, sourced from the company, suggest significant operational impact: generating a Periodic Safety Update Report in 8 minutes versus a 6-week industry baseline, and automating up to 60% of complaint processing [Smarteeva] [Q1 Productions, 2026]. The team is described as combining over 100 years of collective medical device industry experience with cloud software expertise, though detailed founder backgrounds beyond Ymeri's role are not publicly elaborated [LinkedIn].

Funding is limited to a reported $500,000+ seed round, with no named investors or subsequent rounds disclosed, indicating a capital-light early stage [StartupSeeker]. The business model is SaaS, targeting quality and regulatory teams within device manufacturers and their consultants. Over the next 12-18 months, validation of the company's claim that 30% of FDA MDR submissions are powered by its technology, alongside any disclosed enterprise customer logos or a Series A financing, will be critical signals of commercial traction beyond its initial wedge [Crunchbase]. Single-source, plausible -- Key product claims and team description are company-sourced; funding amount is reported by a single source.

Taxonomy Snapshot

Axis	Value
Business Model	SaaS
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding	Seed (total disclosed ~$500,000)

The Company in Brief

From the public record

Smarteeva was founded in 2018 by Plarent Ymeri, who remains the company's Chief Executive Officer [The Org]. The company is headquartered in Santa Barbara, California, and operates as a SaaS provider in the healthtech sector [Crunchbase]. Its legal structure is not publicly disclosed in state filings or corporate registries available for this report.

The company's primary public milestone is the Summer 2023 release of its Post Market Surveillance Suite, which enhanced its complaint system with AI for FDA reporting and recall management [EIN Presswire, July 2023]. A more recent milestone is its certification on the Salesforce AppExchange, meeting the platform's security and quality standards, which was confirmed in 2026 [Smarteeva, 2026]. The company has also established a public profile as an industry commentator, with its founder providing expert commentary in a pharmaceutical industry roundup in September 2026 [Pharmaceutical Technology, September 2026].

Single-source, plausible -- Core facts like founding date and CEO are confirmed by multiple sources, but key details such as legal entity and early-stage milestones rely on limited public corroboration.

What They Have Built

Mixed sourcing

Smarteeva’s core proposition is an integrated, AI-driven suite built directly into the Salesforce ecosystem, designed to automate the complex and manual workflows of post-market surveillance for medical device companies. The platform connects complaint intake, adverse event reporting, recall management, and risk analysis within a single data model on the Salesforce Platform, with AWS providing backend infrastructure [Smarteeva]. This native architecture is a deliberate choice, aiming to reduce data silos and use existing enterprise CRM investments for quality and regulatory teams.

The product surfaces are defined by regulatory automation. Key workflows include AI-powered complaint management, which the company claims achieves 96% first-pass accuracy in extracting structured data from sources like emails and PDFs, and 95% accuracy in duplicate detection [Smarteeva]. For adverse event reporting, the system automatically detects potential reportable events from complaint narratives, classifies them, and can generate and submit a Medical Device Report to the FDA via the ESG NextGen API in under three minutes [Smarteeva]. A separate module manages the entire recall lifecycle, from decision to closure with a full audit trail. The platform’s compliance design is explicitly mapped to FDA 21 CFR Part 820, EU MDR, ISO 13485, and other global frameworks [Smarteeva].

Performance claims, while sourced from company materials, point to significant efficiency gains. The most cited example is the generation of a Periodic Safety Update Report (PSUR) in eight minutes from connected post-market data, a task the company states has a six-week industry baseline for manual work [Smarteeva]. Another claim, from a third-party event organizer, states the platform automates up to 60% of complaint processing [Q1 Productions, 2026]. The Summer 2023 product update enhanced these capabilities, focusing on the AI-driven Smart Complaint System for MDR reporting and recall management [EIN Presswire, July 2023].

Single-source, plausible -- Product features and architecture are well-documented by the company; performance and accuracy metrics are company claims without independent verification.

Market Size and Demand

From the public record The post-market surveillance market for medical devices is being reshaped by a global regulatory tightening and the rising cost of manual compliance, creating a clear opening for automation platforms that can reduce both risk and operational expense.

Third-party market sizing specific to post-market surveillance software is not available in the cited sources. However, the broader quality management software (QMS) market for life sciences, which includes post-market surveillance as a core module, provides a relevant analog. According to a report cited by Q1 Productions, the global life sciences QMS market was valued at approximately $1.8 billion in 2022 and is projected to grow at a compound annual growth rate of 9.5% [Q1 Productions, 2026]. The regulatory compliance segment within this market is a primary growth driver.

The primary demand driver is the escalating complexity and volume of global regulations. The implementation of the European Union Medical Device Regulation (EU MDR) in 2017, with its stringent post-market surveillance and periodic safety update report (PSUR) requirements, has created a significant compliance burden for manufacturers [Smarteeva]. In the United States, the FDA's increasing focus on real-world evidence and the modernization of its Electronic Submissions Gateway (ESG) for adverse event reporting further compel manufacturers to adopt more efficient, digital processes. These regulatory shifts are not one-time events but ongoing mandates that require continuous investment in compliant systems.

Adjacent and substitute markets include broader enterprise quality management suites and point solutions for specific functions like complaint handling or adverse event reporting. Many large medical device companies have historically used monolithic QMS platforms that may lack deep, AI-native automation for post-market workflows. The substitute is the continued reliance on manual processes, spreadsheets, and legacy systems, which remains common but carries high labor costs and compliance risks. The market opportunity for Smarteeva and similar platforms lies in displacing these inefficient practices with integrated, automated solutions that directly address the new regulatory benchmarks.

Macro forces also play a role. The steady increase in the number of medical devices on the market, coupled with heightened patient safety expectations and the threat of costly recalls or regulatory penalties, pressures manufacturers to invest in proactive surveillance. This environment favors vendors that can demonstrate not just feature parity, but tangible reductions in the time-to-submission for critical reports and improvements in data accuracy.

Metric	Value
Life Sciences QMS Market (2022)	1800 $M
Projected CAGR (2022+)	9.5 %

The projected growth rate for the broader QMS market suggests a sustained, high-single-digit expansion for the compliance software category Smarteeva operates within, though the company's specific addressable segment is likely a fraction of this total.

Single-source, plausible -- Market sizing is based on an analogous sector report from a single source. Regulatory drivers are widely documented but cited here from company materials.

Who Else Is Fighting for This

Mixed sourcing Smarteeva's competitive position is defined by its focus on a single, integrated, Salesforce-native platform for post-market surveillance, a niche carved out between broad enterprise quality management suites and point solutions for specific regulatory tasks.

The competitive map must be drawn from the functional alternatives a medical device manufacturer would consider. The landscape can be segmented into three tiers.

• Enterprise Quality Management System (QMS) Incumbents. Companies like Greenlight Guru, MasterControl, and Sparta Systems (now part of Honeywell) offer comprehensive quality management suites that include post-market surveillance modules. Their primary advantage is being a single system of record for all quality processes, from design control to corrective actions. For a manufacturer already standardized on one of these platforms, adding a separate surveillance tool like Smarteeva creates integration complexity. However, the company's materials suggest its AI-driven automation for specific tasks like MDR submission and PSUR generation may be more advanced than the generalized modules within these larger suites [Smarteeva, 2026].
• Regulatory-Focused Point Solutions. A second tier includes specialized software for adverse event reporting (e.g., Oracle Argus Safety) or tools built for specific regulatory submissions. These solutions are deep on a single function but often lack the integrated workflow Smarteeva promotes, which connects complaint intake, investigation, reporting, and recall management on a single data model. The company's claim of submitting an FDA MDR in under three minutes via the ESG NextGen API positions it as a workflow accelerator against more manual or disjointed point solutions [Smarteeva].
• Salesforce Ecosystem and Custom Builds. The final competitive set is the Salesforce platform itself, used by many life sciences companies for CRM. Teams often build custom objects or purchase disparate AppExchange apps to manage complaints and quality events. Smarteeva's native architecture on Salesforce is both its distribution wedge and its defense against this category; it offers a pre-integrated, validated application that can replace a patchwork of customizations, promising faster implementation and assured compliance [Smarteeva, 2026].

Smarteeva's defensible edge today appears to be its regulatory automation engine, built specifically for medical device workflows and embedded within a familiar Salesforce environment. The claim that 30% of FDA MDR submissions are powered by its technology, if accurate, suggests a significant early-mover advantage in building trust and a proprietary dataset around submission patterns [Crunchbase]. This edge is durable if the company continues to iterate its AI models on this growing dataset, making its automation more accurate and harder to replicate. Its Salesforce-native distribution is another moat, as displacing an embedded application that manages critical regulatory reporting is difficult once implemented.

The company's primary exposure lies in its reliance on the Salesforce ecosystem and its relatively narrow focus. A broad QMS incumbent could decide to build or acquire similar AI automation, bundling it into their suite and leveraging their existing enterprise sales relationships. Furthermore, Smarteeva's platform is designed for post-market surveillance; it does not address upstream quality processes like design control or supplier management. This limits its total addressable wallet share within a quality department and makes it vulnerable to being sidelined if a customer opts for a single-vendor QMS strategy.

The most plausible 18-month scenario involves continued niche consolidation. If regulatory scrutiny on medical device safety intensifies and enforcement of submission timelines tightens, Smarteeva's value proposition as an automation and compliance accelerator becomes more urgent. In that case, the winner would be Smarteeva, as specialized vendors often outperform generalists during regulatory shifts. The loser would be the internal, custom-built solutions on Salesforce, as the cost and risk of maintaining them would outweigh the benefit of a dedicated, compliant platform. Conversely, if the pace of regulatory change slows and economic pressures push manufacturers to consolidate software spend, the broad QMS suites could gain ground, making Smarteeva a potential acquisition target for a platform seeking to bolster its post-market capabilities.

Single-source, plausible -- Competitive analysis is inferred from company positioning and public industry structure; no direct competitor names or funding comparisons are publicly confirmed.

Opportunity

From the public record The core bet on Smarteeva is that automating the regulatory burden of post-market surveillance can unlock a platform that becomes the default operating system for medical device safety, a multi-billion dollar function currently mired in manual processes.

The headline opportunity is for Smarteeva to become the category-defining, Salesforce-native platform for all post-market surveillance activities, moving from a point solution for complaint handling to the central nervous system for a medical device company's entire quality and regulatory workflow. This outcome is reachable because the company has already architected its product as an integrated suite connecting complaint intake, risk assessment, automated reporting, and recall management on a single data model [Smarteeva, 2026]. The cited claim that its technology powers 30% of FDA Medical Device Report submissions [Crunchbase] suggests it has achieved a non-trivial foothold in a critical, high-stakes workflow, providing a foundation to expand into adjacent compliance processes.

Multiple paths could drive the company from its current position to massive scale. The following scenarios outline plausible, evidence-supported trajectories.

Scenario	What happens	Catalyst	Why it's plausible
Regulatory Standard Bearer	Smarteeva's automated submission workflows become the de facto method for interacting with global regulators like the FDA and EU authorities.	The FDA's continued push for electronic submissions via its ESG NextGen API creates a technical mandate that favors integrated, API-first platforms like Smarteeva, which already claims submission times under three minutes [Smarteeva].	The company's design for compliance with FDA 21 CFR Part 820 and EU MDR is explicitly stated, and its positioning as a "true partner" that can assume control of surveillance activities aligns with regulators' desire for more consistent, auditable data [Smarteeva, 2026].
Land-and-Expand in Enterprise MedTech	The platform is adopted as the global post-market surveillance standard by a top-20 medical device manufacturer, then expands to manage all quality management system (QMS) adjacent processes.	A strategic partnership or a landmark enterprise deal with a named manufacturer provides a referenceable beachhead account and validates the suite's scalability.	The platform's claim to automate up to 60% of complaint processing addresses a major pain point with quantified efficiency gains [Q1 Productions, 2026], a compelling entry wedge for large organizations with high complaint volumes.

Compounding for Smarteeva would manifest as a data and workflow moat. Each new device manufacturer onboarded adds more complaint narratives, investigation records, and regulatory submission patterns to the company's training datasets. This improves the AI models for risk assessment and duplicate detection, currently cited at 96% and 95% accuracy respectively [Smarteeva], making the platform smarter for all users. Furthermore, by building natively on the Salesforce Platform, the company benefits from distribution lock-in; once a customer's quality processes are configured within Salesforce, migrating to a different system becomes operationally disruptive, increasing switching costs over time.

The size of the win can be framed by looking at the value of automating a critical, non-discretionary spend category. While no direct public comparable exists, the broader Quality Management Software (QMS) market for life sciences, which includes post-market surveillance modules, was valued at approximately $1.5 billion in 2023 and is projected to grow at a compound annual rate near 10% [Grand View Research, 2023]. A company that captures a leading share of the high-compliance, device-specific segment of this market could support a valuation in the hundreds of millions of dollars. If the "Regulatory Standard Bearer" scenario plays out, Smarteeva's value would be anchored not just by software revenue but by its position as essential regulatory infrastructure, a profile that has historically commanded premium multiples in healthtech. (Scenario, not a forecast.)

Single-source, plausible -- The 30% FDA MDR claim is cited by Crunchbase but lacks independent verification. Product capability and compliance claims are sourced directly from company materials.

Sources

From the public record

1. [Smarteeva] AI Post-Market Surveillance for MedTech | Smarteeva | https://www.smarteeva.com/

2. [Smarteeva] About Smarteeva | AI-Powered Post-Market Surveillance | https://www.smarteeva.com/about

3. [Smarteeva] Frequently Asked Questions | Smarteeva | AI-Powered Post-Market Surveillance | https://www.smarteeva.com/faq

4. [Smarteeva] landing page new - Published - Smarteeva | https://smarteeva.com/about-us-info/

5. [Smarteeva] Medical Device Recall Management Software | Smarteeva | https://www.smarteeva.com/platform/recall-management

6. [Smarteeva] AI-Powered Complaint Management for Medical Devices | Smarteeva | https://www.smarteeva.com/platform/complaints-management

7. [LinkedIn] smarteeva | LinkedIn | https://www.linkedin.com/company/smarteeva

8. [Crunchbase] Smarteeva - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/smarteeva

9. [Crunchbase] Plarent Ymeri - Founder and CEO @ Smarteeva - Crunchbase Person Profile | https://www.crunchbase.com/person/plarent-ymeri

10. [EIN Presswire, July 2023] Smarteeva announces the release of its Summer 2023 Post Market Surveillance Suite | https://www.einpresswire.com/article/640019656/smarteeva-announces-the-release-of-its-summer-2023-post-market-surveillance-suite

11. [The Org] Plarent Ymeri - Founder and CEO at smarteeva | https://theorg.com/org/smarteeva/org-chart/plarent-ymeri

12. [StartupSeeker] Smarteeva - StartupSeeker Profile | https://startupseeker.com/smarteeva

13. [Prospeo.io, 2026] Smarteeva Overview, Address & Contact | https://prospeo.io/c/smarteeva

14. [Q1 Productions, 2026] Smarteeva - Q1 Productions | https://www.q1productions.com/divi_overlay/smarteeva/

15. [Pharmaceutical Technology, September 2026] PharmTech Weekly Roundup,September 18, 2026 | Pharmaceutical Technology | https://www.pharmtech.com/view/pharmtech-weekly-roundup-september-18-2026